Related Experiment Video
Updated: Nov 9, 2025
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
12.0K
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Sarah I M Sutherland1,2,3,4, Xinsheng Ju1,2, L G Horvath2,4,5
1Dendritic Cell Research, ANZAC Research Institute, Concord, NSW, Australia.
Frontiers in Immunology
|April 15, 2021
Summary
Dendritic cell (DC) immunotherapy shows promise for prostate cancer (PCa) by improving survival. However, newer strategies using monocyte-derived DCs (MoDC) have faced challenges, necessitating advanced antigen delivery and combination therapies for better efficacy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumors employ diverse mechanisms to evade immune surveillance, with checkpoint inhibitors showing success in several cancers but resistance in prostate cancer (PCa).
- Sipuleucel-T, a dendritic cell (DC) immunotherapy, demonstrated improved overall survival (OS) in PCa, yet subsequent DC vaccine development has stalled, limiting clinical application.
- Prostate cancer (PCa) exhibits an immunosuppressive microenvironment driven by both adaptive and innate immunity, characterized by dysfunctional and immature DCs, creating a tolerogenic milieu.
Purpose of the Study:
- To review the reasons behind the limited clinical success of newer monocyte-derived DC (MoDC) vaccine strategies in PCa.
- To highlight advanced antigen loading and presentation technologies for enhancing DC vaccine efficacy.
- To explore combination strategies to counteract the immunosuppressive tumor microenvironment in PCa.
Main Methods:
- Review of existing literature on DC-based immunotherapies for prostate cancer.
- Analysis of factors contributing to the failure of MoDC vaccines.
- Evaluation of emerging antigen delivery systems (nanoparticles, antibody-antigen conjugates, virus co-delivery).
Main Results:
- While Sipuleucel-T showed initial OS benefit, further DC vaccine progress has been limited.
- Dysfunctional and immature DCs in PCa contribute to an immunosuppressive and tolerogenic environment.
- Emerging technologies offer potential to improve antigen presentation and DC vaccine efficacy.
Conclusions:
- Prostate cancer (PCa) remains a viable candidate for DC-based immunotherapy due to its inherent immune-suppressive characteristics.
- Advanced antigen loading and presentation technologies are crucial for overcoming current limitations in MoDC vaccine efficacy.
- Combination strategies are essential to address the immunosuppressive tumor microenvironment and enhance therapeutic outcomes in PCa.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
605
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
605
01:27Tumor Immunotherapy
816
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816
01:51Vaccinations
48.9K
Overview
48.9K